Education
About Us
Working with TipRanks
Follow Us
SanBio Co Ltd (SNBIF)
OTHER OTC:SNBIF
SNBIF Stock Chart & Stats
$10.11
$0.00(0.00%)
At close: 4:00 PM EST
$10.11
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$6.55 - $23.00
Previous CloseN/A
Volume950.00
Average Volume (3M)8.00
Market Cap
$1.03B
Enterprise Value$168.40B
Total Cash (Recent Filing)$2.74B
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Mar 23, 2026EPS Estimate
-20.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding78,033,330
10 Day Avg. Volume25
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-5.05
Price to Book (P/B)28.13
Price to Sales (P/S)0.00
P/FCF Ratio-13.74
Enterprise Value/Market Cap163.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-20.39K
Enterprise Value/Ebitda-38.28
Forecast
1Y Price Target
$13.01Price Target Upside28.70% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$23.06M
Bulls Say, Bears Say
Bulls Say
Proprietary Platform & Focused PipelineSanBio’s proprietary cell-therapy platform and focused CNS/regenerative pipeline create a durable scientific moat. Specialization in stroke and neurological indications raises technical barriers to entry, supporting long-term value creation if clinical milestones are met.
Reduced Debt / Moderate LeverageDebt has come down materially and leverage is moderate, lowering near-term refinancing pressure. A reduced debt load improves financial flexibility to fund development via non-debt alternatives and reduces interest burden while advancing clinical programs.
Narrowing Net Loss TrendReported net losses narrowed in 2024–2025 versus 2023, signaling operational progress or expense control. A sustained improvement in the loss trajectory reduces cumulative cash burn and enhances the probability of reaching clinical inflection points with less dilution.
Bears Say
No Commercial RevenueReported zero revenue from 2021–2025 indicates the business remains pre-revenue with no commercial cash flows. Long-term value depends entirely on successful R&D and regulatory approvals, increasing funding dependency and binary outcome risk for investors.
Persistent Cash BurnOperating and free cash flow are negative every year and cash burn remains substantial. Persistent negative FCF forces continual financing, increasing dilution and refinancing risk and narrowing strategic options if clinical timelines slip or markets tighten.
Balance-sheet Erosion / Negative ReturnsEquity has declined sharply and ROE is deeply negative, signaling balance-sheet erosion from cumulative losses. A weakened equity base reduces shock absorption, limits borrowing capacity and heightens vulnerability to adverse trial or funding events.
SanBio Co News
SNBIF FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was $6.55 and its highest was $23.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is $1.03B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Mar 23, 2026 which is in 16 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Dec 15, 2025. The company reported -$0.063 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.034.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Undervalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -20.69.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,033,330 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -$0.063 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in SNBIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
SNBIF Stock 12 Month Forecast
Average Price Target
$13.01
▲(28.70% Upside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
― Other Institutional Investors
98.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---